Seo Jeong-jin, Chairman of Celltrion Group, presented a goal to increase global new drug sales to 5 trillion won by 2030, focusing on 'Zymfentra', which was recently approved as a new drug in the United States.

Chairman Seo made this announcement at a press conference held at NH Investment & Securities in Seoul on the 25th.

Previously, Celltrion set the group's total sales target of 12 trillion won in 2030. The plan is to increase sales by adding new drugs as well as existing biosimilars. Chairman Seo predicted that Zimfentra would play a pivotal role here. Zymfentra is the subcutaneous (SC) formulation of Remsima. On the 20th (local time), it received sales approval as a new drug from t